- 全部删除
您的购物车当前为空
IL-1RA Protein, Human, Recombinant (HEK293) is expressed in HEK293 Cells. The accession number is P18510.

| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 5 μg | ¥ 338 | 6-8日内发货 | |
| 10 μg | ¥ 539 | 6-8日内发货 | |
| 20 μg | ¥ 723 | 5日内发货 | |
| 50 μg | ¥ 1,080 | 5日内发货 | |
| 100 μg | ¥ 1,820 | 5日内发货 | |
| 200 μg | ¥ 2,970 | 5日内发货 | |
| 500 μg | ¥ 6,290 | 5日内发货 | |
| 1 mg | ¥ 10,800 | 5日内发货 |
| 生物活性 | ED 50 < 0.1 μg /ml, measured in a neutralization assay using D10S cells in the presence of 50.0 pg/ml Human IL-1a. |
| 产品描述 | IL-1RA Protein, Human, Recombinant (HEK293) is expressed in HEK293 Cells. The accession number is P18510. |
| 种属 | Human |
| 表达系统 | HEK293 Cells |
| 标签 | Tag Free |
| 蛋白编号 | P18510 |
| 别名 | IRAP,IL-1RN,IL1RA,ICIL-1RA |
| 蛋白构建 | Arg26-Glu177 |
| 蛋白纯度 | > 95% as determined by SDS-PAGE; > 95% as determined by HPLC |
| 分子量 | 18~23 kDa (Reducing conditions) |
| 内毒素 | < 0.2 EU/μg of protein as determined by the LAL method. |
| 缓冲液 | Lyophilized from a 0.2 μm filtered solution in PBS. |
| 复溶方法 | Reconstitute the lyophilized protein in sterile deionized water. The product concentration should not be less than 100 μg/ml. Before opening, centrifuge the tube to collect powder at the bottom. After adding the reconstitution buffer, avoid vortexing or pipetting for mixing. |
| 存储 | Upon receiving, this product remains stable for up to 6 months at lower than -70°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. For long term storage it is recommended that a carrier protein (example 0.1% BSA) be added. Avoid repeated freeze-thaw cycles. |
| 运输方式 | In general, Lyophilized powders are shipping with blue ice. Solutions are shipping with dry ice. |
| 研究背景 | IL-1 Receptor Antagonist, also known as IL-1RA, ICIL-1RA, IRAP and IL-1RN, is a member of the interleukin 1 cytokine family. It is expressed by monocytes, neutrophils, macrophages, epithelial cells and fibroblasts. IL-1RA inhibits the activity of both IL-1alpha and IL-1beta, and modulates a variety of IL-1 related immune and inflammatory responses. It inhibits the activity of IL-1 by binding to the receptor IL-1R1 and preventing its association with the coreceptor IL-1RAP for signaling. Clinical studies are being conducted to investigate the use of IL-1RA in the treatment of sepsis, rheumatoid arthritis and chronic myelogenous leukemia. |